<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35171147</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><Issue>M2</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Documento de consenso sobre el uso de iSGLT2 en pacientes con enfermedad renal cr&#xf3;nica y diabetes.</ArticleTitle><Pagination><StartPage>M1</StartPage><EndPage>M12</EndPage><MedlinePgn>M1-M12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.M21000595</ELocationID><Abstract><AbstractText>La enfermedad renal cr&#xf3;nica (ERC) del paciente diab&#xe9;tico es frecuentemente una consecuencia directa de la diabetes mellitus (DM) de larga evoluci&#xf3;n y se la conoce como nefropat&#xed;a diab&#xe9;tica. En M&#xe9;xico cerca del 50% de los pacientes en terapia sustitutiva de la funci&#xf3;n renal tienen ERC por DM, y este porcentaje podr&#xed;a aumentar en los pr&#xf3;ximos a&#xf1;os. Nuevas opciones terap&#xe9;uticas, combinadas con cambios en el estilo de vida, han mejorado el control de la glucemia y pueden contribuir sustancialmente a retrasar la aparici&#xf3;n o la progresi&#xf3;n a estadios avanzados de la ERC. Las sociedades cient&#xed;ficas internacionales han elaborado gu&#xed;as cl&#xed;nicas para el diagn&#xf3;stico y manejo de la nefropat&#xed;a diab&#xe9;tica, sin embargo, en algunos puntos estas recomendaciones no se adaptan a la realidad mexicana. Se presentan las conclusiones de un consenso realizado por especialistas mexicanos sobre diabetes y ERC, con especial &#xe9;nfasis en el uso de los inhibidores del cotransportador de sodio-glucosa. Chronic kidney disease (CKD) in the diabetic patient is mainly a consequence of long-term diabetes mellitus itself. In Mexico approximately 50% of patients on dialysis are diabetics and this will could increase in the coming years. New therapeutic options available, combined with lifestyle changes, have improved glycemic control and may contribute to delay the onset as well as the progression of CKD. International scientific societies have developed clinical guidelines for the diagnosis and management of CKD in diabetics, although in some points, these recommendations are not adapted to the Mexican reality. We hereby present the conclusions of the consensus reached by Mexican specialists on diabetic nephropathy.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Correa-Rotter</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Nefrolog&#xed;a y Metabolismo Mineral, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas-Guzm&#xe1;n</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Diabetes AC en Celaya, Celaya, Guanajuato. M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Especialidades M&#xe9;dicas de Celaya, Celaya, Guanajuato. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-Dur&#xe1;n</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Coordinaci&#xf3;n de Programas M&#xe9;dicos Nivel Central, Instituto Mexicano del Seguro Social (IMSS), Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebasti&#xe1;n-D&#xed;az</LastName><ForeName>Mario A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a, Hospital Central Sur de Alta Especialidad, Petr&#xf3;leos Mexicanos (PEMEX), Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Avenda&#xf1;o</LastName><ForeName>Odette Del C</ForeName><Initials>ODC</Initials><AffiliationInfo><Affiliation>Servicio de Nefrolog&#xed;a y Trasplante Renal, Hospital Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta-Pravin</LastName><ForeName>Roopa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n de Enfermedades Metab&#xf3;licas (UIEM), Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcocer-Gamba</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Instituto de Coraz&#xf3;n de Quer&#xe9;taro, Quer&#xe9;taro, Quer&#xe9;taro. M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Quer&#xe9;taro, Quer&#xe9;taro, Quer&#xe9;taro. M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Consesus document in the use of SGLT inhibitors in patients with diabetes and chronic kidney disease.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Diabetes tipo 2</Keyword><Keyword MajorTopicYN="N">Enfermedad renal cr&#xf3;nica</Keyword><Keyword MajorTopicYN="N">Nefropat&#xed;a diab&#xe9;tica</Keyword><Keyword MajorTopicYN="N">Recomendaciones</Keyword><Keyword MajorTopicYN="N">Recommendations</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">iSGLT2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35171147</ArticleId><ArticleId IdType="doi">10.24875/GMM.M21000595</ArticleId><ArticleId IdType="pii">j158/M2/M1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35120107</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2444-054X</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Cirugia y cirujanos</Title><ISOAbbreviation>Cir Cir</ISOAbbreviation></Journal><ArticleTitle>Hypozincemia in Mexican patients with diabetic foot ulcer treated out of hospital.</ArticleTitle><Pagination><StartPage>34</StartPage><EndPage>40</EndPage><MedlinePgn>34-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/CIRU.20001065</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To know the frequency of people with hypozincemia in a group of Mexican patients with Diabetic Foot Ulcers (DFU)m and its relationship with metabolic and clinical profile.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Cross-sectional, analytical, and observational study in patients with and without DFU, treated in Family Medicine Units from Instituto Mexicano del Seguro Social (IMSS) in M&#xe9;rida, Yucat&#xe1;n, M&#xe9;xico. Frequency of hypozincemia (Zn serum &lt; 70 g/ml) and its relationship with the levels of Glycosylated Hemoglobin (HbA1c), cholesterol and triglycerides was analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">70% of patients with DFU and 25% without DFU had hypozincemia (OR = 5.2, 95% CI 2.139-12.65, p = 0.0004). Patients with hypozincemia were older and the highest prevalence was between 50 and 60 years. The average area of the DFU showed no differences in patients with and without hypozincemia. Patients with DFU reported higher levels of HbA1c, cholesterol, triglycerides, BMI, and blood pressure compared to patients without DFU. Hypozincemia was associated with higher BMI values.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The frequency of hypozincemia in diabetic patients with UPD is high and is behaving as a risk factor for presenting UPD, so its identification should be routine.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xe1;nchez-Cruz</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Delegaci&#xf3;n Estatal en Yucat&#xe1;n, M&#xe9;rida, Yucat&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar-Alonso</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias Qu&#xed;micas, Benem&#xe9;rita Universidad Aut&#xf3;noma de Puebla, Puebla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio-Zapata</LastName><ForeName>H&#xe9;ctor A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Universidad Aut&#xf3;noma de Yucat&#xe1;n, M&#xe9;rida, Yucat&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Flores</LastName><ForeName>Elideth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Unidad de Medicina Familiar No. 58 del IMSS, M&#xe9;rida Yucat&#xe1;n. M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Hipozinquemia en pacientes mexicanos con &#xfa;lcera de pie diab&#xe9;tico tratados en el primer nivel de atenci&#xf3;n.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Cir Cir</MedlineTA><NlmUniqueID>0372736</NlmUniqueID><ISSNLinking>0009-7411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017719" MajorTopicYN="Y">Diabetic Foot</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Conocer la frecuencia de hipozinquemia en pacientes Mexicanos con &#xfa;lceras de pie diab&#xe9;tico (UPD) y su relacion con el perfil cl&#xed;nico y metab&#xf3;lico.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">Estudio transversal, anal&#xed;tico, en pacientes con y sin &#xfa;lceras de pie diab&#xe9;tico, tratados en unidades de medicina familiar del Instituto Mexicano del Seguro Social (IMSS) en M&#xe9;rida, Yucat&#xe1;n, M&#xe9;xico, que analiz&#xf3; la frecuencia de Hipozinquemia (Zn serico de &lt; 70 mg/ml) y su relaci&#xf3;n con los niveles de Hemoglobina Glucosilada (HbA1c), colesterol y triglic&#xe9;ridos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">70% de los pacientes con UPD y 25% sin UPD ten&#xed;an hipoziquemia (OR=5.2, IC95% 2.139-12.65, p=0.0004). La mayor prevalencia se encontr&#xf3; entre los 50 y 60 a&#xf1;os. El &#xe1;rea promedio de las UPD no mostr&#xf3; diferencias entre pacientes con y sin hipozinquemia. Los pacientes con UPD presentaron niveles m&#xe1;s altos de HbA1c (p&lt;0.001), colesterol (p&lt;0.001), triglic&#xe9;ridos (p&lt;0.001), IMC (p=0.01) y tensi&#xf3;n arterial (p=0.009) en comparaci&#xf3;n con los pacientes sin UPD. Los pacientes con UPD e hipoziquemia ten&#xed;an mayores valores de IMC.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">La frecuencia de hipozinquemia en pacientes diab&#xe9;ticos con UPD es alta y es se comporte como un factor de riesgo para presentar UPD, por lo que su identificaci&#xf3;n deberia ser rutinaria.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Metabolismo</Keyword><Keyword MajorTopicYN="N">Wounds</Keyword><Keyword MajorTopicYN="N">Zinc</Keyword><Keyword MajorTopicYN="N">&#xda;lceras</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35120107</ArticleId><ArticleId IdType="doi">10.24875/CIRU.20001065</ArticleId><ArticleId IdType="pii">j90/1/34</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34544583</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2530-3120</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Revista Colombiana de psiquiatria</Title><ISOAbbreviation>Rev Colomb Psiquiatr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Perceived Stress by Students of the Medical Sciences in Cuba Toward the COVID-19 Pandemic: Results of an Online Survey.</ArticleTitle><Pagination><StartPage>176</StartPage><EndPage>183</EndPage><MedlinePgn>176-183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rcpeng.2021.02.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2530-3120(21)00083-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aims of this study were to determine the usefulness of the Modified (10-item) Scale of Perceived Stress related to COVID-19 (EEP-10-C, for its acronym in Spanish) and to identify the levels of stress perceived by students of medical sciences in Cuba due to the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional study was conducted, with self-reported data of students from 14 Cuban universities of medical sciences (n=200), through an online survey. The EEP-10-C was used as an instrument to identify stress. Its validity was determined through a confirmatory factor analysis and its internal consistency and reliability was measured by the Cronbach's alpha. A cluster analysis was performed to establish as the cut-off point the centre of the cluster with the highest values of stress perceived by the scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The average age of the sample was 23.30&#xb1; 1.91 years, with observed scores of the EEP-10-C between 0 and 29 points (13.25&#xb1;5.404). When applying the cut-off point &#x2265;25, only two&#xa0;students had high rates of perceived stress. The confirmatory factor analysis supported the validity of the instrument (&#x3b1;=0.755). The cut-off point &#x2265;20 was proposed as a reference of high stress perceived for the study population, when applying this one, 14% of students presented high rates of stress.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In Cuba, students of the medical sciences have participated in research and healthcare support, despite which they have presented low levels of stress. The main contribution of the research was the validation of the EEP-10-C for its use in assessing levels of stress in Cuban medical students, proposing the cut-off point &#x2265;20 as a reference of high stress perceived.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Asociaci&#xf3;n Colombiana de Psiquiatr&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Garc&#xed;a</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro Provincial de Atenci&#xf3;n y Educaci&#xf3;n al Paciente Diab&#xe9;tico, Hospital Provincial General Docente "Dr. Antonio Luaces Iraola", Facultad de Ciencias M&#xe9;dicas "Dr. Jos&#xe9; AsseF Yara", Universidad de Ciencias M&#xe9;dicas de Ciego de &#xc1;vila, Ciego de &#xc1;vila, Cuba. Electronic address: frankhernandezgarcia1996@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;ngora G&#xf3;mez</LastName><ForeName>Onelis</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias M&#xe9;dicas Mariana Grajales Coello, Universidad de Ciencias M&#xe9;dicas de Holgu&#xed;n, Holgu&#xed;n, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Vel&#xe1;zquez</LastName><ForeName>Victor Ernesto</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad de Ciencias M&#xe9;dicas de Villa Clara, Villa Clara, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedraza-Rodr&#xed;guez</LastName><ForeName>Elys Mar&#xed;a</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad de Ciencias M&#xe9;dicas de Villa Clara, Villa Clara, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamora-Fung</LastName><ForeName>Rolando</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias M&#xe9;dicas Enrique Cabrera, Universidad de Ciencias M&#xe9;dicas de La Habana, La Habana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazo Herrera</LastName><ForeName>Luis Alberto</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias M&#xe9;dicas Dr. Ernesto Che Guevara de la Serna, Universidad de Ciencias M&#xe9;dicas de Pinar del R&#xed;o, Pinar del R&#xed;o, Cuba.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Colomb Psiquiatr (Engl Ed)</MedlineTA><NlmUniqueID>101778593</NlmUniqueID><ISSNLinking>2530-3120</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Rev Colomb Psiquiatr (Engl Ed). 2021 Jul-Sep;50(3):164-165. doi: 10.1016/j.rcpeng.2021.05.004.</RefSource><PMID Version="1">34544582</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010465" MajorTopicYN="N">Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="Y">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="Y">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013337" MajorTopicYN="N">Students, Medical</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Estr&#xe9;s psicol&#xf3;gico</Keyword><Keyword MajorTopicYN="N">Estudiantes de Medicina</Keyword><Keyword MajorTopicYN="N">Medical students</Keyword><Keyword MajorTopicYN="N">Psychological stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34544583</ArticleId><ArticleId IdType="doi">10.1016/j.rcpeng.2021.02.003</ArticleId><ArticleId IdType="pii">S2530-3120(21)00083-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33244905</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2306-4102</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Acta ortopedica mexicana</Title><ISOAbbreviation>Acta Ortop Mex</ISOAbbreviation></Journal><ArticleTitle>[Identification by images of the patient with diabetic foot of the type of injuries that required or will require amputation].</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>80</EndPage><MedlinePgn>77-80</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Diabetes is a chronic-degenerative disease that develops after pancreatic dysfunction. An estimated 422 million people in the world are currently diagnosed with diabetes. One of its most common complications is diabetic foot. It is estimated that about 15% of diabetic patients will have lower extremities ulcers.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">It is an observational, descriptive, prospective and cross-sectional study. It aims to know what the initial injuries that triggered an amputation in a complicated diabetic foot. Patients were presented with clinical photographs with images typical of pathologies for recognition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 50 patients were included between January 2017 and July 2019. Of these 78% (38) patients were male, 22% (11) female. 22 patients (44%) recognized as the onset of diabetic foot an ulcer, 13 with blisters (26%), 10 with hyperkeratosis (20%), 5 with hammer toes (10%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">96% of patients were able to identify at least one injury as a predisposing factor for the onset of their complicated diabetic foot. The presentation of clinical photographs proved to be a patient-accepted tool. By identifying their initial injury we can determine which injury and where, where, it gave rise to the complication that led them to amputation. This information can help to perform preventive measures to limit amputations in the pelvic limbs of diabetic patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>King-Mart&#xed;nez</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Ortopedia. Hospital General &#xab;Dr. Manuel Gea Gonz&#xe1;lez&#xbb;. Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doger-Echegaray</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio Social de la Divisi&#xf3;n de Ortopedia. Hospital General &#xab;Dr. Manuel Gea Gonz&#xe1;lez&#xbb;. Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyo-P&#xe9;rez</LastName><ForeName>L I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Ortopedia. Hospital General &#xab;Dr. Manuel Gea Gonz&#xe1;lez&#xbb;. Ciudad de M&#xe9;xico. M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Identificaci&#xf3;n por im&#xe1;genes del paciente con pie diab&#xe9;tico del tipo de lesiones que requirieron o requerir&#xe1;n amputaci&#xf3;n.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Acta Ortop Mex</MedlineTA><NlmUniqueID>101190312</NlmUniqueID><ISSNLinking>2306-4102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000671" MajorTopicYN="N">Amputation, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017719" MajorTopicYN="Y">Diabetic Foot</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">La diabetes es una enfermedad cr&#xf3;nico degenerativa que se desarrolla posterior a una disfunci&#xf3;n del p&#xe1;ncreas. Se estima que actualmente hay 422 millones de personas en el mundo que cuentan con el diagn&#xf3;stico de diabetes. Una de sus complicaciones m&#xe1;s frecuentes es el pie diab&#xe9;tico. Se estima que alrededor de 15% de los pacientes diab&#xe9;ticos tendr&#xe1;n &#xfa;lceras en las extremidades inferiores.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">Es un estudio observacional, descriptivo, prospectivo y transversal. Su objetivo es conocer cu&#xe1;les son las lesiones iniciales que desencadenaron una amputaci&#xf3;n en un pie diab&#xe9;tico complicado. A los pacientes se les mostraron fotograf&#xed;as cl&#xed;nicas con las im&#xe1;genes t&#xed;picas de las patolog&#xed;as para su reconocimiento.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se incluy&#xf3; un total de 50 pacientes entre Enero de 2017 y Julio de 2019. De &#xe9;stos, 78% (38) pacientes fueron masculinos, 22% (11) femeninos. 22 pacientes (44%) reconocieron el inicio del pie diab&#xe9;tico con una &#xfa;lcera, 13 con flictenas (26%), 10 con hiperqueratosis (20%), cinco con dedos en martillo (10%).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">96% de los pacientes lograron identificar al menos una lesi&#xf3;n como factor predisponente para la aparici&#xf3;n de pie diab&#xe9;tico complicado. La presentaci&#xf3;n de fotograf&#xed;as cl&#xed;nicas result&#xf3; ser una herramienta aceptada por los pacientes. Mediante la identificaci&#xf3;n de su lesi&#xf3;n inicial podemos determinar qu&#xe9; lesi&#xf3;n y en qu&#xe9; sitio dio origen a la complicaci&#xf3;n que los llev&#xf3; a la amputaci&#xf3;n. Esta informaci&#xf3;n puede contribuir a tomar medidas preventivas para limitar las amputaciones en los miembros p&#xe9;lvicos de los pacientes diab&#xe9;ticos.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetic foot</Keyword><Keyword MajorTopicYN="N">amputation</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">treatment</Keyword><Keyword MajorTopicYN="N">ulcers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33244905</ArticleId><ArticleId IdType="pii">S2306-4102(20)95318-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33156748</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2171-8695</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</Title><ISOAbbreviation>Farm Hosp</ISOAbbreviation></Journal><ArticleTitle>Insulin eye drops for treating corneal ulcer in a non-diabetic patient: regarding a case.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>299</EndPage><MedlinePgn>297-299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7399/fh.11521</ELocationID><Abstract><AbstractText>Corneal ulcers are included in a heterogeneous group of eye injuries.&#xa0;When&#xa0; patients do not respond to treatment, including even corneal transplant,&#xa0;other&#xa0; alternatives need to be explored.We present a case of a patient who suffered an accidental spillage&#xa0;from the&#xa0; contents of a car battery. This corneal lesion was refractory to both&#xa0;surgical and&#xa0; pharmacological treatment. After four years of a persistent&#xa0;ulcer, insulin topical&#xa0; treatment 50 IU/mL was started. Improvement began to&#xa0;be observed and&#xa0; currently the patient has completely recovered the corneal&#xa0;epithelium.Nowadays, evidence of the topical insulin use for the treatment of corneal&#xa0;ulcers&#xa0; is higher in diabetic patients. In non-diabetic patients, evidence&#xa0;is restricted to a series of cases of neurotrophic corneal ulcers and a case&#xa0;report of a patient who&#xa0; presented a persistent epithelial defect after resection&#xa0;of a neurinoma. This case&#xa0; presents the experience of using an insulin&#xa0;drop formulation with effectiveness&#xa0; and absence of toxicity in a patient nondiabetic&#xa0;with a post-caustic corneal ulcer.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serrano-Gim&#xe9;nez</LastName><ForeName>Reyes</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Universitario Virgen de Valme, Sevilla. Spain.. reysergim@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras-Mac&#xed;as</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Universitario Virgen de Valme, Sevilla. Spain.. enriquecm92@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Bernal</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Hospital Universitario Virgen de Valme, Sevilla, Spain.. anam.garcia.bernal.sspa@juntadeandalucia.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fobelo-Lozano</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Universitario Virgen de Valme, Sevilla. Spain.. mariaj.fobelo.sspa@juntadeandalucia.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Insulina t&#xf3;pica en el tratamiento de &#xfa;lcera corneal refractaria en un paciente no diab&#xe9;tico: a prop&#xf3;sito de un caso.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Farm Hosp</MedlineTA><NlmUniqueID>9440679</NlmUniqueID><ISSNLinking>1130-6343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009883">Ophthalmic Solutions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003320" MajorTopicYN="Y">Corneal Ulcer</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019573" MajorTopicYN="Y">Epithelium, Corneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009883" MajorTopicYN="N">Ophthalmic Solutions</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las &#xfa;lceras corneales se incluyen dentro de un grupo heterog&#xe9;neo de&#xa0;lesiones&#xa0; oculares, las cuales pueden ser de gravedad variable. Cuando&#xa0;los pacientes no&#xa0; responden al tratamiento, incluyendo incluso el trasplante&#xa0;corneal, se crea la&#xa0; necesidad de explorar otras alternativas.Presentamos el caso de un paciente que sufri&#xf3; una salpicadura ocular&#xa0;del&#xa0; contenido de una bater&#xed;a de autom&#xf3;vil por accidente. Esta lesi&#xf3;n&#xa0;corneal, fue&#xa0; refractaria al tratamiento farmacol&#xf3;gico e incluso quir&#xfa;rgico.&#xa0;Tras cuatro a&#xf1;os de persistencia de la &#xfa;lcera corneal, se inici&#xf3; un tratamiento&#xa0;t&#xf3;pico con insulina 50&#xa0; UI/ml. Se observ&#xf3; mejor&#xed;a de forma evidente&#xa0;y actualmente el paciente ha&#xa0; recuperado completamente el epitelio&#xa0;corneal.Hoy en d&#xed;a, las evidencias disponibles del uso t&#xf3;pico de la insulina&#xa0;para el&#xa0; tratamiento de las &#xfa;lceras corneales se centran en pacientes diab&#xe9;ticos.&#xa0;En los&#xa0; pacientes no diab&#xe9;ticos, la evidencia se limita a una serie&#xa0;de casos de &#xfa;lceras&#xa0; neurotr&#xf3;ficas corneales y al caso de un paciente que&#xa0;present&#xf3; un defecto&#xa0; epitelial persistente despu&#xe9;s de la resecci&#xf3;n de un&#xa0;neurinoma. Este caso,&#xa0; presenta la experiencia de uso de una formulaci&#xf3;n&#xa0;magistral de insulina&#xa0; oft&#xe1;lmica con eficacia y ausencia de toxicidad en un&#xa0;paciente no diab&#xe9;tico con&#xa0; una &#xfa;lcera corneal post-c&#xe1;ustica resistente al&#xa0;resto de tratamientos.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>17</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33156748</ArticleId><ArticleId IdType="doi">10.7399/fh.11521</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32576384</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Atencion primaria</Title><ISOAbbreviation>Aten Primaria</ISOAbbreviation></Journal><ArticleTitle>[Diabetic patient control in Primary Care: Influence of service portfolio and other factors].</ArticleTitle><Pagination><StartPage>617</StartPage><EndPage>626</EndPage><MedlinePgn>617-626</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aprim.2020.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0212-6567(20)30105-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To study the effect of the type of follow-up according to Service Portfolio and other associated factors, in the reduction of HbA<sub>1c</sub> levels in people with a new diagnosis of type 2 diabetes and poor initial control.</AbstractText><AbstractText Label="DESIGN">Analytical observational study of a cohort under routine clinical practice conditions.</AbstractText><AbstractText Label="LOCATION">262 Primary Health Care Centres in Madrid.</AbstractText><AbstractText Label="PARTICIPANTS">1,838 individuals older than 18 years with a new diagnosis of type 2 DM and initial HbA1c levels &#x2265; 7%, or &#x2265; 8.5% if older than 75 years.</AbstractText><AbstractText Label="INTERVENTIONS">The exposure variable was the type of follow-up according to Portfolio, categorised as minimum, medium, and optimal, according to the number of interventions performed and periodicity of type of therapeutic-pharmacological plan.</AbstractText><AbstractText Label="MAIN MEASUREMENTS">A study was made of the comorbidity, therapeutic-pharmacological plan, diet - exercise advice and deprivation index. The main outcome was the difference between the final and initial HbA1c.</AbstractText><AbstractText Label="RESULTS">After 2 years of follow-up there was a mean decrease in HbA<sub>1c</sub> by -1.7 percentage points (95% CI: -1.6;-1.8), which was 0.36 points higher in patients with optimal follow-up: -2.1 (95% CI: -1.7;-2.4). The factors associated with a decrease in HbA1c were the optimal follow-up -0.29 (95% CI: -0.5;-0.1), the medium follow-up -0.26 (95% CI: -0.5; -0.0), and the initial HbA1c value -0.9 (95% CI: -0.9; -0.9. The factors associated with the increase were insulin treatment and living in socially disadvantaged areas.</AbstractText><AbstractText Label="CONCLUSIONS">Glycaemic control was improved in patients with a new diagnosis of diabetes in which optimal follow-up is performed as proposed in the Service Portfolio.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bay&#xf3;n Cabeza</LastName><ForeName>Marianela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n T&#xe9;cnica de Procesos y Calidad, Gerencia Asistencial de Atenci&#xf3;n Primaria, Servicio Madrile&#xf1;o de Salud, Comunidad de Madrid, Madrid, Espa&#xf1;a. Electronic address: marianela.bayon@salud.madrid.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Rivas</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n T&#xe9;cnica de Procesos y Calidad, Gerencia Asistencial de Atenci&#xf3;n Primaria, Servicio Madrile&#xf1;o de Salud, Comunidad de Madrid, Madrid, Espa&#xf1;a; Departamento de Enfermer&#xed;a, Facultad de Enfermer&#xed;a, Fisioterapia y Podolog&#xed;a, Universidad Complutense de Madrid, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamora Sarabia</LastName><ForeName>Ana Leonor</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Las Heras Mosteiro</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Preventiva, Salud P&#xfa;blica, e Inmunolog&#xed;a y Microbiolog&#xed;a, Universidad Rey Juan Carlos, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerril Rojas</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unidad de Apoyo T&#xe9;cnico, Gerencia Adjunta de Procesos Asistenciales, Gerencia Asistencial de Atenci&#xf3;n Primaria, Servicio Madrile&#xf1;o de Salud, Comunidad de Madrid, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez Barrientos</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de apoyo a la investigaci&#xf3;n, Gerencia Asistencial de Atenci&#xf3;n Primaria, Servicio Madrile&#xf1;o de Salud, Comunidad de Madrid, Madrid, Espa&#xf1;a; Investigaci&#xf3;n en Servicios de Salud y Enfermedades Cr&#xf3;nicas (REDISSEC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Control del paciente diab&#xe9;tico en Atenci&#xf3;n Primaria: influencia de cartera de servicios y otros factores.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Aten Primaria</MedlineTA><NlmUniqueID>9111075</NlmUniqueID><ISSNLinking>0212-6567</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO">Estudiar el efecto del tipo de seguimiento seg&#xfa;n la cartera de servicios y de otros factores asociados en la disminuci&#xf3;n de las cifras de HbA<sub>1c</sub> en personas con diabetes mellitus tipo 2, nuevo diagn&#xf3;stico y con mal control inicial.</AbstractText><AbstractText Label="DISE&#xd1;O">Estudio observacional anal&#xed;tico de una cohorte en condiciones de pr&#xe1;ctica cl&#xed;nica habitual.</AbstractText><AbstractText Label="EMPLAZAMIENTO">262 centros de salud de Atenci&#xf3;n Primaria de Madrid.</AbstractText><AbstractText Label="PARTICIPANTES">1838 personas mayores de 18 a&#xf1;os con nuevo diagn&#xf3;stico de diabetes y cifras de HbA<sub>1c</sub> inicial &#x2265; 7% o &#x2265; 8,5% si tienen m&#xe1;s de 75 a&#xf1;os.</AbstractText><AbstractText Label="INTERVENCIONES">La variable exposici&#xf3;n fue el tipo de seguimiento seg&#xfa;n la cartera, categorizado en m&#xed;nimo, medio y &#xf3;ptimo, seg&#xfa;n el n&#xfa;mero de intervenciones realizadas y periodicidad por tipo de plan terap&#xe9;utico-farmacol&#xf3;gico.</AbstractText><AbstractText Label="MEDICIONES PRINCIPALES">Se estudiaron comorbilidad, plan terap&#xe9;utico-farmacol&#xf3;gico, consejos dieta y ejercicio, &#xed;ndice de privaci&#xf3;n. La variable resultado principal fue la diferencia entre la HbA<sub>1c</sub> final e inicial.</AbstractText><AbstractText Label="RESULTADOS">Tras 2 a&#xf1;os de seguimiento se produjo una disminuci&#xf3;n media de la HbA<sub>1c</sub> de &#x2013;1,7 puntos porcentuales (IC del 95%: &#x2013;1,6; &#x2013;1,8), siendo 0,39 puntos mayor en los pacientes con tipo de seguimiento &#xf3;ptimo: &#x2013;2,1 (IC del 95%: &#x2013;1,7; &#x2013;2,4). Los factores asociados a la disminuci&#xf3;n fueron: tipo de seguimiento &#xf3;ptimo &#x2013;0,29 (IC del 95%: &#x2013;0,5; &#x2013;0,1) y medio &#x2013;0,26 (IC del 95%: &#x2013;0,5; &#x2013;0,0), y valor de la HbA<sub>1c</sub> inicial &#x2013;0,9 (IC del 95%: &#x2013;0,9; &#x2013;0,9) y los factores asociados al aumento: tratamiento con insulina y vivir en zonas socialmente desfavorecidas.</AbstractText><AbstractText Label="CONCLUSIONES">Los pacientes con diagn&#xf3;stico reciente de diabetes en los que se realiza un seguimiento &#xf3;ptimo seg&#xfa;n la cartera de servicios mejoran el control gluc&#xe9;mico.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atenci&#xf3;n Primaria de salud</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus tipo 2</Keyword><Keyword MajorTopicYN="N">Efectividad de intervenciones</Keyword><Keyword MajorTopicYN="N">Effectiveness of interventions</Keyword><Keyword MajorTopicYN="N">Evaluaci&#xf3;n de resultado (atenci&#xf3;n de salud)</Keyword><Keyword MajorTopicYN="N">Glycated haemoglobin A</Keyword><Keyword MajorTopicYN="N">Hemoglobina glucosilada</Keyword><Keyword MajorTopicYN="N">Outcome assessment (health care)</Keyword><Keyword MajorTopicYN="N">Primary Health Care</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32576384</ArticleId><ArticleId IdType="pmc">PMC7713397</ArticleId><ArticleId IdType="doi">10.1016/j.aprim.2020.02.015</ArticleId><ArticleId IdType="pii">S0212-6567(20)30105-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global report on diabetes. World Health Organization, Geneva, 2016. [Consultado 29 Ene 2018]. Disponible en: http://www.who.int/mediacentre/factsheets/fs312/en/</Citation></Reference><Reference><Citation>Instituto Nacional de Estad&#xed;stica . INE; Madrid: 2018. Encuesta Nacional de Salud 2016-2017.</Citation></Reference><Reference><Citation>Gandarillas A.M., del Pino V., Ordob&#xe1;s M., Donoso E., Izquierdo C., Arrieta F.J. Direcci&#xf3;n General de Salud P&#xfa;blica Consejer&#xed;a de Sanidad; Madrid: 2018. Prevalencia de diabetes mellitus y riesgo cardiovascular en poblaci&#xf3;n adulta de la Comunidad de Madrid: estudio PREDIMERC 2015.</Citation></Reference><Reference><Citation>Nathan D.M. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 2014;37:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867999</ArticleId><ArticleId IdType="pubmed">24356592</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405&#x2013;412. 10 TFM.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27454</ArticleId><ArticleId IdType="pubmed">10938048</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Standards of medical care in diabetes. Diabetes Care. 2017;40(Suppl 1) [Consultado 29 Ene 2018]. Disponible en: http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf.</Citation></Reference><Reference><Citation>National Institute for Health and Clinical Excellence . NICE; London: 2015. Type 2 diabetes in adults: Management (NG28)</Citation><ArticleIdList><ArticleId IdType="pubmed">26741015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad, Servicios Sociales e Igualdad . Ministerio de Sanidad Servicios Sociales e Igualdad; Madrid: 2012. Estrategia en diabetes del Sistema Nacional de Salud. Actualizaci&#xf3;n.</Citation></Reference><Reference><Citation>Gerencia Asistencial de Atenci&#xf3;n Primaria de Madrid . Servicio Madrile&#xf1;o de Salud, Gerencia Asistencial de Atenci&#xf3;n Primaria de Madrid; Madrid: 2016. Cartera de servicios estandarizados de Atenci&#xf3;n Primaria de Madrid. Revisi&#xf3;n 2016.</Citation></Reference><Reference><Citation>Badia X., del Llano J. Investigaci&#xf3;n de resultados en salud. Med Clin (Barc). 2000;114(Supl. 3):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10994557</ArticleId></ArticleIdList></Reference><Reference><Citation>Garz&#xf3;n Gonz&#xe1;lez G. Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud. Departamento de Medicina Preventiva y Salud P&#xfa;blica e Inmunolog&#xed;a y Microbiolog&#xed;a M&#xe9;dicas; Madrid: 2011. Asociaci&#xf3;n entre los indicadores cl&#xed;nicos institucionales de proceso y de resultado en atenci&#xf3;n primaria en la Comunidad de Madrid [tesis doctoral]</Citation></Reference><Reference><Citation>Parra P., Gomis R., Mart&#xed;nez V., Calle J.E., Garijo Y., Canovas A. Normas t&#xe9;cnicas y control metab&#xf3;lico del paciente diab&#xe9;tico en atenci&#xf3;n primaria de la Regi&#xf3;n de Murcia. Rev Cal Asist. 2003;18:87&#x2013;92.</Citation></Reference><Reference><Citation>D&#xed;az J.M., Garc&#xed;a de Celis M.J., Hevia L.A., Morales F.J., Vecino J.A., Forcada J.E. Normas t&#xe9;cnicas m&#xed;nimas y control metab&#xf3;lico de la diabetes en un centro de salud. Medifam. 1996;6:345&#x2013;351.</Citation></Reference><Reference><Citation>Segovia C., Ma&#xed;n A., Corral L., Gonz&#xe1;lez E., Raquejo M.A., Nart&#xed;n E. Control metab&#xf3;lico de la diabetes mellitus en relaci&#xf3;n con la calidad de las historias cl&#xed;nicas. Aten Primaria. 2000;26:670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681401</ArticleId><ArticleId IdType="pubmed">11200510</ArticleId></ArticleIdList></Reference><Reference><Citation>Garz&#xf3;n G., Gil A., Alvaro A., Rodrigo R., Cerezo M.J., Dom&#xed;nguez C. Asociaci&#xf3;n entre indicadores de proceso medidos sobre historia electr&#xf3;nica y resultados intermedios en salud, en pacientes con diabetes. Rev Calid Asist. 2013;28:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara E., Herv&#xe1;s R., Gonz&#xe1;lez M.T., Salas F., Mu&#xf1;oz P., Velasco A. Predicci&#xf3;n del grado de control metab&#xf3;lico por las normas t&#xe9;cnicas m&#xed;nimas en el programa de diabetes. Aten Primaria. 1997;19:313&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez E., Ferr&#xe9; F., Jim&#xe9;nez L., de Dios J. Valoraci&#xf3;n de los factores relacionados con el control de la glucemia en la diabetes mellitus tipo 2. Aten Primaria. 1999;24:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">10427904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bay&#xf3;n M. P&#xe9;rez F.J. S&#xe1;nchez L. Mart&#xed;nez M.D. Bartolome E. Rodr&#xed;guez D. &#xbf;Existe relaci&#xf3;n entre nuestros procesos asistenciales a pacientes cr&#xf3;nicos y los resultados intermedios en salud? XXXII Congreso de la Sociedad Espa&#xf1;ola de Calidad Asistencial. Madrid 15-17 de octubre del 2014</Citation></Reference><Reference><Citation>Bay&#xf3;n M. P&#xe9;rez F.J. Rodr&#xed;guez R. Mart&#xed; M. Mart&#xed;nez M.D. Alonso T. Procesos asistenciales efectivos: &#xbf;mejora la salud de las personas diab&#xe9;ticas con nuestra pr&#xe1;ctica cl&#xed;nica? XXXIII Congreso de la Sociedad Espa&#xf1;ola de Calidad Asistencial. Gij&#xf3;n 14-16 de octubre del 2015</Citation></Reference><Reference><Citation>Bay&#xf3;n M. P&#xe9;rez F.J. Rodr&#xed;guez R. Becerril B. Malillos D. las Heras J.et.al. Procesos asistenciales efectivos: &#xbf;mejora la salud de las personas diab&#xe9;ticas con nuestra pr&#xe1;ctica cl&#xed;nica? XXXIV Congreso de la Sociedad Espa&#xf1;ola de Calidad Asistencial. C&#xf3;rdoba 19-21 de octubre del 2016</Citation></Reference><Reference><Citation>Horga F. Ergon; Madrid: 2015. El rol de la investigaci&#xf3;n en efectividad comparada (CER)</Citation></Reference><Reference><Citation>Armstrong K. Methods in comparative effectiveness research. J Clin Oncol. 2012;30:4208&#x2013;4214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3504326</ArticleId><ArticleId IdType="pubmed">23071240</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J., Lawler E.V., Lew R.A., Gaziano J.M., Aslan M., Huang G.D. Observational methods in comparative effectiveness research. Am J Med. 2010;123:e16&#x2013;e23.</Citation><ArticleIdList><ArticleId IdType="pubmed">21184862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez-Berj&#xf3;n M.F., Borrell C., Cano-Serral G., Esnaola S., Nolasco A., Pasar&#xed;n M.I. Construcci&#xf3;n de un &#xed;ndice de privaci&#xf3;n a partir de datos censales en grandes ciudades espa&#xf1;olas (Proyecto MEDEA) Gac Sanit. 2008;22:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">18579042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarol J.N., Jr., Nicodemus N.A., Jr., Tan K.M., Grava M.B. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: A meta-analysis (1966-2004) Curr Med Res Opin. 2005;21:173&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">15801988</ArticleId></ArticleIdList></Reference><Reference><Citation>Olry de Labry A., Berm&#xfa;dez C., Pastor G., Bol&#xed;var J., Ruiz I., Johri M. Efectividad de una intervenci&#xf3;n para mejorar los resultados cl&#xed;nicos con autogesti&#xf3;n de la diabetes en pacientes con bajo nivel educativo. Gac Sanit. 2017;31:40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Church T.S., Blair S.N., Cocreham S., Johannsen N., Johnson W., Kramer K. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2010;304:2253&#x2013;2262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174102</ArticleId><ArticleId IdType="pubmed">21098771</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppell K.J., Kataoka M., Williams S.M., Chisholm A.W., Vorgers S.M., Mann J.I. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment &#x2014;Lifestyle. Over and Above Drugs in Diabetes (LOADD) Study: Randomised controlled trial. BMJ. 2010;341:c3337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907481</ArticleId><ArticleId IdType="pubmed">20647285</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoriza J.M., Iba&#xf1;ez A., P&#xe9;rez-Berruezo X., Inoriza-Nadal C., Coderch J. Efectividad e impacto econ&#xf3;mico de un programa de atenci&#xf3;n integrada con soporte de telemedicina a pacientes diab&#xe9;ticos tipo 2 tratados con insulina (estudio GITDIABE) Aten Primaria. 2017;49:131&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876025</ArticleId><ArticleId IdType="pubmed">27423246</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodgren G., Rachas A., Farmer A.J., Inzitari M., Shepperd S. Inter-active telemedicine: Effects on professional practice and healthcare outcomes. Cochrane database Syst Rev. 2015;9:CD002098. doi: 10.1002/14651858.CD002098.pub230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002098.pub230</ArticleId><ArticleId IdType="pmc">PMC6473731</ArticleId><ArticleId IdType="pubmed">26343551</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z., Tao H., Meng Q., Jing L. Effects of telecare intervention on glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol. 2015;172:R93&#x2013;R101.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett W.L., Maruthur N.M., Singh S., Segal J.B., Wilson L.M., Chatterjee R. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733115</ArticleId><ArticleId IdType="pubmed">21403054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolen S.D., Chandar A., Falck-Ytter C., Tyler C., Perzynski A.T., Gertz A.M. Effectiveness and safety of patient activation interventions for adults with type 2 diabetes: systematic review meta-analysis and meta-regression. J Gen Intern Med. 2014;29:1166&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4099447</ArticleId><ArticleId IdType="pubmed">24733301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrvala C.A., Sherr D., Lipman R.D. Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control. Patient Educ Couns. 2016;99:926&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">26658704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz M., Escolar A., Mayoral E., Corral F., Fern&#xe1;ndez I. La diabetes mellitus en Espa&#xf1;a: mortalidad, prevalencia, incidencia, costes econ&#xf3;micos y desigualdades. Gac Sanit. 2006;20(Supl 1):15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16539961</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;lez A., Fern&#xe1;ndez B., Toca C., Amasuno M., L&#xf3;pez N., Tasc&#xf3;n L. Evaluaci&#xf3;n de los objetivos del triple control alcanzado spor pacientes con diabetes mellitus tipo 2 atendidos en las consultas de atenci&#xf3;n primaria de una zona b&#xe1;sica de salud. Med Gen y Fam. 2016;5:45&#x2013;48.</Citation></Reference><Reference><Citation>Garz&#xf3;n G., Gil A., Herrero A., Jim&#xe9;nez F., Cerezo M., Dom&#xed;nguez C. Grado de control metab&#xf3;lico y de factores de riesgo cardiovascular en pacientes con diabetes tipo 2 con y sin enfermedad cardiovascular. Gac Sanit. 2015;29:425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">26342408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez B., Galbete A., Go&#xf1;i M.J., Forga L., Arnedo L., Aizpuru F. Socioeconomic inequalities in cardiometabolic control in patients with type 2 diabetes. BMC Public Health. 2018;18:408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5869771</ArticleId><ArticleId IdType="pubmed">29587788</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinagre I., Mata-Cases M., Hermosilla E., Morros R., Fina F., Rosell M. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain) Diabetes Care. 2012;35:774&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308283</ArticleId><ArticleId IdType="pubmed">22344609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>